Chronic phospholamban inhibition prevents progressive cardiac dysfunction and pathological remodeling after infarction in rats.
about
Dobutamine stress echocardiography in healthy adult male rats.Model-specific selection of molecular targets for heart failure gene therapyGene delivery technologies for cardiac applicationsCardiovascular gene therapy for myocardial infarctionGene therapy targets in heart failure: the path to translationMicroRNAs in heart failure: Small molecules with major impactCalcium mishandling in diastolic dysfunction: mechanisms and potential therapiesCardiac-targeted delivery of regulatory RNA molecules and genes for the treatment of heart failureHeart failure-inducible gene therapy targeting protein phosphatase 1 prevents progressive left ventricular remodelingCine-MRI versus two-dimensional echocardiography to measure in vivo left ventricular function in rat heart.Heart failure management: the present and the future.Phospholamban ablation rescues sarcoplasmic reticulum Ca(2+) handling but exacerbates cardiac dysfunction in CaMKIIdelta(C) transgenic miceAltered intracellular Ca2+ handling in heart failure.Increased infarct wall thickness by a bio-inert material is insufficient to prevent negative left ventricular remodeling after myocardial infarction.Cardiac gene therapyUpdate on gene therapy for myocardial ischaemia and left ventricular systolic dysfunction or heart failure.A novel artificial microRNA expressing AAV vector for phospholamban silencing in cardiomyocytes improves Ca2+ uptake into the sarcoplasmic reticulum.Phospholamban phosphorylation, mutation, and structural dynamics: a biophysical approach to understanding and treating cardiomyopathy.Cardiac gene transfer of short hairpin RNA directed against phospholamban effectively knocks down gene expression but causes cellular toxicity in canines.AAV vectors for cardiac gene transfer: experimental tools and clinical opportunities.Atomic-level mechanisms for phospholamban regulation of the calcium pump.Mechanical stress-strain sensors embedded in cardiac cytoskeleton: Z disk, titin, and associated structures.Targeting cardiomyocyte Ca2+ homeostasis in heart failure.Models of dilated cardiomyopathy in small animals and novel positive inotropic therapies.Molecular aspects of ischemic heart disease: ischemia/reperfusion-induced genetic changes and potential applications of gene and RNA interference therapy.New signaling pathways associated with increased cardiac adenylyl cyclase 6 expression: implications for possible congestive heart failure therapy.Creation of a cardiotropic adeno-associated virus: the story of viral directed evolution.Gene therapy in the treatment of heart failure.Gene therapy in heart failure.Toward biologically targeted therapy of calcium cycling defects in heart failure.Remodeling of calcium handling in human heart failure.Delta-sarcoglycan gene therapy halts progression of cardiac dysfunction, improves respiratory failure, and prolongs life in myopathic hamstersPhospholamban overexpression in rabbit ventricular myocytes does not alter sarcoplasmic reticulum Ca transportAn emerging adeno-associated viral vector pipeline for cardiac gene therapyDesigning heart performance by gene transfer.Beta-adrenergic stimulation and myocardial function in the failing heart.Antiplatelet therapy attenuates subcellular remodelling in congestive heart failure.Factors controlling the activity of the SERCA2a pump in the normal and failing heart.Return of calcium: manipulating intracellular calcium to prevent cardiac pathologiesAdvances in gene-based therapy for heart failure.
P2860
Q24812916-AFBEF0A3-3361-4ED1-8487-CFE04CE31F50Q26823061-D30F98B9-B539-4677-8741-0BFEFCB7DE96Q26863362-03FC7FB4-670F-4450-AB17-1D127EE6660FQ27014770-8DA788E5-391D-414B-9638-DFC8FC77246BQ27022444-7A26397E-452C-4D8A-A7B1-80957FBFA59BQ27024714-0C6F5F04-C434-4122-9F67-52DCA41895BEQ27026716-BE712697-19E9-41B2-812B-9E424A883A44Q27691424-EA34F859-FF0D-4EA8-9185-617AC71B2C27Q28482901-90258DFA-AEFA-44F5-B92B-2B1A79CBE7EEQ33331753-859FCB85-1B30-4C32-916A-D2D4810C6C36Q33605156-502BC6B1-546C-4761-B8B1-691B34F1F2EFQ33639652-1D61CA87-4298-47F4-B05B-44956C128C77Q33683757-E4952502-8B81-44CA-BB1A-FBF2AF50FCC4Q33952558-79F72CA4-E6FE-482A-966C-CF61DC1AA7A1Q34409721-14FB9985-9E04-4F99-8EB8-896D4950319AQ35069886-DC9EDB88-7B85-40C0-961F-E4A6859E80E5Q35132004-630BD5C9-10E1-4BCA-B14A-482511F7AB6FQ35169578-09AC3902-CF54-4516-A68C-9B1BD14DE9C0Q35174923-95B72EF6-8044-4CE3-A077-D5DDA0139B39Q35238264-646ED12C-B5DE-4371-952D-01CA0659A564Q35333572-6F45DF96-6B31-47CD-824C-E031FD606B18Q35621909-87B87877-CA75-4A0A-987E-E1F8F7DB1B66Q35763705-64924C0F-7B95-4633-AEA2-D66090F5772FQ35807774-F470A794-B2FD-41B8-AB75-A9B4868E3CFAQ36480080-0CA35807-068B-4C7D-BDB0-E64942EC2D02Q36515530-77149F85-0BF8-42B2-8663-FCE2021AD088Q36614445-AD7B52E7-CF54-4130-9AAF-66D4C479AA36Q36786243-F08D382F-962D-4BDF-BEFF-7D0E525A81D0Q36944623-B9063186-534C-4C30-A65A-E4A050A30EA3Q37082359-BD82E667-D922-448C-8C2D-0F0BC58616EBQ37088473-A9144A44-2CF9-4FEA-94CD-91FC62413BDAQ37092093-8C4F1189-F97B-458E-BF99-3653A8C927B0Q37138913-B5208250-00AA-4AA6-B257-6C1F1D2E2A2AQ37272838-B70FE51C-0AB8-4374-9413-B67D4CA3D2A8Q37299072-C6BB88E3-1022-4D7F-BD17-7D922DBDA235Q37358922-63718CAC-CD83-468D-9E9D-6E0BF04B9114Q37568760-04210B38-13C4-484C-9DA0-7252DDDB6686Q37630987-8D26AA0E-A739-4BC8-AE3C-5FF15C016DD2Q37644605-A78D17CF-CD61-41E6-A873-BA118048F341Q37766138-29DDE1FE-B452-4D01-9BEC-EFAEA91BF21E
P2860
Chronic phospholamban inhibition prevents progressive cardiac dysfunction and pathological remodeling after infarction in rats.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Chronic phospholamban inhibiti ...... ling after infarction in rats.
@ast
Chronic phospholamban inhibiti ...... ling after infarction in rats.
@en
type
label
Chronic phospholamban inhibiti ...... ling after infarction in rats.
@ast
Chronic phospholamban inhibiti ...... ling after infarction in rats.
@en
prefLabel
Chronic phospholamban inhibiti ...... ling after infarction in rats.
@ast
Chronic phospholamban inhibiti ...... ling after infarction in rats.
@en
P2093
P2860
P1476
Chronic phospholamban inhibiti ...... eling after infarction in rats
@en
P2093
Jacqueline Chrast
Kenneth R Chien
Kirk L Peterson
Masahiko Hoshijima
Masunori Matsuzaki
Mitsuo Iwatate
Moto-o Date
Yoshitaka Iwanaga
P2860
P304
P356
10.1172/JCI18716
10.1172/JCI200418716
P407
P577
2004-03-01T00:00:00Z